| Year |
Citation |
Score |
| 2024 |
Lantermans HC, Ma F, Kuil A, van Kesteren S, Yasinoglu S, Yang G, Buhrlage SJ, Wang J, Gray NS, Kersten MJ, Treon SP, Pals ST, Spaargaren M. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma. Leukemia. PMID 38454120 DOI: 10.1038/s41375-024-02207-9 |
0.306 |
|
| 2024 |
Wang L, Bohmer MJ, Wang J, Nardella F, Calla J, Laureano De Souza M, Schindler KA, Montejo L, Mittal N, Rocamora F, Treat M, Charlton JT, Tumwebaze PK, Rosenthal PJ, Cooper RA, et al. Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases. Journal of Medicinal Chemistry. PMID 38214254 DOI: 10.1021/acs.jmedchem.3c02046 |
0.528 |
|
| 2023 |
Bohmer MJ, Wang J, Istvan ES, Luth MR, Collins JE, Huttlin EL, Wang L, Mittal N, Hao M, Kwiatkowski NP, Gygi SP, Chakrabarti R, Deng X, Goldberg DE, Winzeler EA, et al. Human Polo-like Kinase Inhibitors as Antiplasmodials. Acs Infectious Diseases. PMID 36919909 DOI: 10.1021/acsinfecdis.3c00025 |
0.555 |
|
| 2023 |
Teng M, Jiang J, Wang ES, Geng Q, Toenjes ST, Donovan KA, Mageed N, Yue H, Nowak RP, Wang J, Manz TD, Fischer ES, Cantley LC, Gray NS. Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader. Angewandte Chemie (International Ed. in English). e202302364. PMID 36898968 DOI: 10.1002/anie.202302364 |
0.488 |
|
| 2022 |
Zhang J, Pearson AJ, Sabherwal N, Telfer BA, Ali N, Kan K, Xu Q, Zhang W, Chen F, Li S, Wang J, Gray NS, Risa-Ebrí B, Finegan KG, Cross MJ, et al. Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition. Cancer Research Communications. 2: 131-145. PMID 36466034 DOI: 10.1158/2767-9764.CRC-21-0089 |
0.448 |
|
| 2022 |
Boytz R, Słabicki M, Ramaswamy S, Patten JJ, Zou C, Meng C, Hurst BL, Wang J, Nowak RP, Yang PL, Sattler M, Stone RM, Griffin JD, Gray NS, Gummuluru S, et al. Anti-SARS-CoV-2 Activity of Targeted Kinase Inhibitors: Repurposing Clinically Available Drugs for COVID-19 Therapy. Journal of Medical Virology. PMID 36117402 DOI: 10.1002/jmv.28157 |
0.461 |
|
| 2022 |
Morita K, He S, Nowak RP, Wang J, Zimmerman MW, Fu C, Durbin AD, Martel MW, Prutsch N, Gray NS, Fischer ES, Look AT. Retraction Notice to: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell. 185: 3058. PMID 35931023 DOI: 10.1016/j.cell.2022.07.008 |
0.382 |
|
| 2022 |
Li Z, Ishida R, Liu Y, Wang J, Li Y, Gao Y, Jiang J, Che J, Sheltzer JM, Robers MB, Zhang T, Westover KD, Nabet B, Gray NS. Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European Journal of Medicinal Chemistry. 238: 114433. PMID 35597007 DOI: 10.1016/j.ejmech.2022.114433 |
0.529 |
|
| 2022 |
Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Palomba ML, Argyropoulos KV, Patterson CJ, Canning AG, Meid KE, Gustine J, Branagan AR, Flynn C, Sarosiek S, ... ... Wang J, et al. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances. PMID 35255496 DOI: 10.1182/bloodadvances.2021006147 |
0.466 |
|
| 2021 |
Privalsky TM, Soohoo AM, Wang J, Walsh CT, Wright GD, Gordon EM, Gray NS, Khosla C. Prospects for Antibacterial Discovery and Development. Journal of the American Chemical Society. 143: 21127-21142. PMID 34860516 DOI: 10.1021/jacs.1c10200 |
0.429 |
|
| 2021 |
Kaltheuner IH, Anand K, Moecking J, Düster R, Wang J, Gray NS, Geyer M. Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nature Communications. 12: 6607. PMID 34785661 DOI: 10.1038/s41467-021-26935-z |
0.51 |
|
| 2021 |
Tang CC, Castro Andrade CD, O'Meara MJ, Yoon SH, Sato T, Brooks DJ, Bouxsein ML, Martins JDS, Wang J, Gray NS, Misof B, Roschger P, Boulin S, Klaushofer K, Velduis-Vlug A, et al. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. Elife. 10. PMID 34160349 DOI: 10.7554/eLife.67772 |
0.359 |
|
| 2021 |
Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos M, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid KE, et al. The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. PMID 34132782 DOI: 10.1182/blood.2021011405 |
0.446 |
|
| 2021 |
Remenyi J, Naik RJ, Wang J, Razsolkov M, Verano A, Cai Q, Tan L, Toth R, Raggett S, Baillie C, Traynor R, Hastie CJ, Gray NS, Arthur JSC. Generation of a chemical genetic model for JAK3. Scientific Reports. 11: 10093. PMID 33980892 DOI: 10.1038/s41598-021-89356-4 |
0.502 |
|
| 2021 |
Wells CI, Al-Ali H, Andrews DM, Asquith CRM, Axtman AD, Dikic I, Ebner D, Ettmayer P, Fischer C, Frederiksen M, Futrell RE, Gray NS, Hatch SB, Knapp S, Lücking U, ... ... Wang J, et al. The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. International Journal of Molecular Sciences. 22. PMID 33429995 DOI: 10.3390/ijms22020566 |
0.496 |
|
| 2020 |
Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. PMID 33275901 DOI: 10.1016/j.cell.2020.10.038 |
0.48 |
|
| 2020 |
Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Correction to "Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6-benzo[]pyrimido[5,4-][1,4]diazepin-6-one Scaffold". Journal of Medicinal Chemistry. PMID 32790356 DOI: 10.1021/acs.jmedchem.0c01338 |
0.494 |
|
| 2020 |
Schröder M, Tan L, Wang J, Liang Y, Gray NS, Knapp S, Chaikuad A. Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. Cell Chemical Biology. PMID 32783966 DOI: 10.1016/J.Chembiol.2020.07.014 |
0.55 |
|
| 2020 |
Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167. PMID 32778962 DOI: 10.1007/S11095-020-02851-7 |
0.553 |
|
| 2020 |
Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology. PMID 32755567 DOI: 10.1016/J.Chembiol.2020.07.011 |
0.541 |
|
| 2020 |
Giurisato E, Lonardi S, Telfer B, Lussoso S, Risa-Ebrí B, Zhang J, Russo I, Wang J, Santucci A, Finegan KG, Gray NS, Vermi W, Tournier C. Extracellular-regulated protein kinase 5-mediated control of p21 expression promotes macrophage proliferation associated with tumor growth and metastasis. Cancer Research. PMID 32561530 DOI: 10.1158/0008-5472.Can-19-2416 |
0.479 |
|
| 2020 |
Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and structure activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. Journal of Medicinal Chemistry. PMID 32530623 DOI: 10.1021/Acs.Jmedchem.0C00596 |
0.56 |
|
| 2020 |
Morita K, He S, Nowak RP, Wang J, Zimmerman MW, Fu C, Durbin AD, Martel MW, Prutsch N, Gray NS, Fischer ES, Look AT. Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell. PMID 32315619 DOI: 10.1016/J.Cell.2020.03.051 |
0.521 |
|
| 2020 |
Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology. PMID 32251410 DOI: 10.1038/S41589-020-0506-0 |
0.591 |
|
| 2020 |
Lochhead PA, Tucker JA, Tatum NJ, Wang J, Oxley D, Kidger AM, Johnson VP, Cassidy MA, Gray NS, Noble MEM, Cook SJ. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications. 11: 1383. PMID 32170057 DOI: 10.1038/S41467-020-15031-3 |
0.585 |
|
| 2020 |
Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. PMID 32144400 DOI: 10.1038/S41375-020-0782-4 |
0.452 |
|
| 2020 |
Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, Adamia S, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer. PMID 32015510 DOI: 10.1038/S41416-020-0731-Z |
0.557 |
|
| 2020 |
Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, ... ... Wang J, et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal. 10: 12. PMID 32005797 DOI: 10.1038/S41408-020-0277-6 |
0.493 |
|
| 2020 |
Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, Adamia S, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of Cellular and Molecular Medicine. PMID 31967735 DOI: 10.1111/Jcmm.14927 |
0.559 |
|
| 2020 |
Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Toure AA, Buhrlage S, Liu X, Wang J, Gray N, Stone R, Adamia S, Winer E, Sattler M, Griffin JD. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. Journal of Cellular and Molecular Medicine. PMID 31943762 DOI: 10.1111/Jcmm.14820 |
0.59 |
|
| 2020 |
Morita K, He S, Nowak RP, Wang J, Zimmerman MW, Fu C, Durbin AD, Gray NS, Fischer ES, Look AT. Abstract 3408: Targeting cancer cells with potent activators of the PP2A protein phosphatase tumor suppressor Cancer Research. 80: 3408-3408. DOI: 10.1158/1538-7445.Am2020-3408 |
0.411 |
|
| 2019 |
de Wispelaere M, Carocci M, Burri DJ, Neidermyer WJ, Olson CM, Roggenbach I, Liang Y, Wang J, Whelan SPJ, Gray NS, Yang PL. A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation. The Journal of Biological Chemistry. PMID 31914414 DOI: 10.1074/Jbc.Ra119.011132 |
0.527 |
|
| 2019 |
Tarumoto Y, Lin S, Wang J, Milazzo JP, Xu Y, Lu B, Yang Z, Wei Y, Polyanskaya S, Wunderlich M, Gray NS, Stegmaier K, Vakoc CR. Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo. Blood. PMID 31697837 DOI: 10.1182/Blood.2019001576 |
0.588 |
|
| 2019 |
Lian W, Jang J, Potisopon S, Li PC, Rahmeh A, Wang J, Kwiatkowski NP, Gray NS, Yang PL. Correction to Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. Acs Infectious Diseases. PMID 31675213 DOI: 10.1021/Acsinfecdis.9B00401 |
0.465 |
|
| 2019 |
Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. PMID 31455850 DOI: 10.1038/S41375-019-0552-3 |
0.463 |
|
| 2019 |
Tang X, Drotar J, Li K, Clairmont CD, Brumm AS, Sullins AJ, Wu H, Liu XS, Wang J, Gray NS, Sur M, Jaenisch R. Pharmacological enhancement of gene expression exerts therapeutic effects on human Rett syndrome neurons and mutant mice. Science Translational Medicine. 11. PMID 31366578 DOI: 10.1126/Scitranslmed.Aau0164 |
0.492 |
|
| 2019 |
Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology. PMID 31309543 DOI: 10.1111/Bjh.16092 |
0.556 |
|
| 2019 |
Wu Y, Wang B, Wang J, Qi S, Zou F, Qi Z, Liu F, Liu Q, Chen C, Hu C, Hu Z, Wang A, Wang L, Wang W, Ren T, et al. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry. PMID 31250638 DOI: 10.1021/Acs.Jmedchem.9B00280 |
0.301 |
|
| 2019 |
Moret N, Clark NA, Hafner M, Wang Y, Lounkine E, Medvedovic M, Wang J, Gray N, Jenkins J, Sorger PK. Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries. Cell Chemical Biology. PMID 30956147 DOI: 10.1016/J.Chembiol.2019.02.018 |
0.517 |
|
| 2019 |
Pitts J, Hsia CY, Lian W, Wang J, Pfeil MP, Kwiatkowski N, Li Z, Jang J, Gray NS, Yang PL. Identification of small molecule inhibitors targeting the Zika virus envelope protein. Antiviral Research. PMID 30771406 DOI: 10.1016/J.Antiviral.2019.02.008 |
0.491 |
|
| 2019 |
Li PC, Jang J, Hsia CY, Groomes P, Lian W, de Wispelaere M, Pitts JD, Wang J, Kwaitkowski N, Gray NS, Yang PL. Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo. Acs Infectious Diseases. PMID 30608640 DOI: 10.1021/Acsinfecdis.8B00322 |
0.49 |
|
| 2019 |
Yang G, Wang J, Liu X, Munshi M, Chen JG, Kofides A, Xu L, Tsakmaklis N, Demos M, Guerrera ML, Chan GG, Jimenez C, Hunter ZR, Patterson C, Castillo JJ, et al. A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas Blood. 134: 394-394. DOI: 10.1182/Blood-2019-130636 |
0.532 |
|
| 2019 |
Lin S, Tarumoto Y, Wang J, Milazzo J, Xu Y, Gray N, Vakoc C, Stegmaier K. Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia Blood. 134: 3941-3941. DOI: 10.1182/Blood-2019-125278 |
0.572 |
|
| 2019 |
Morita K, He S, Nowak RP, Wang J, Gray N, Fischer ES, Look AT. Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor Blood. 134: 406-406. DOI: 10.1182/Blood-2019-123573 |
0.478 |
|
| 2019 |
Szalat R, Lawlor M, Fulciniti M, Epstein CB, Xu Y, Samur A, Lin C, Rao P, farrell N, Wu S, Schwartz L, Wen K, Tai Y, Wang J, Gray N, et al. Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e8-e9. DOI: 10.1016/J.Clml.2019.09.011 |
0.413 |
|
| 2018 |
Liang X, Wang B, Chen C, Wang A, Hu C, Zou F, Yu K, Liu Q, Li F, Hu Z, Lu T, Wang J, Wang L, Weisberg E, Li L, et al. Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent Fms-like Tyrosine Kinase 3 Internal Tandem Duplications (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. Journal of Medicinal Chemistry. PMID 30565931 DOI: 10.1021/Acs.Jmedchem.8B01594 |
0.369 |
|
| 2018 |
Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 7. PMID 30422115 DOI: 10.7554/Elife.39030 |
0.518 |
|
| 2018 |
Liu X, Wang B, Chen C, Jiang Z, Hu C, Wu H, Zhang Y, Liu X, Wang W, Wang J, Hu Z, Wang A, Huang T, Liu Q, Wang W, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. European Journal of Medicinal Chemistry. 160: 61-81. PMID 30317026 DOI: 10.1016/J.Ejmech.2018.10.007 |
0.328 |
|
| 2018 |
Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, et al. Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains. Acs Chemical Biology. PMID 30102854 DOI: 10.2210/Pdb6Cd5/Pdb |
0.695 |
|
| 2018 |
Czarna A, Wang J, Zelencova D, Liu Y, Deng X, Choi HG, Zhang T, Zhou W, Chang JW, Kildalsen H, Seternes OM, Gray NS, Engh RA, Rothweiler U. Novel scaffolds for Dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A) inhibitors. Journal of Medicinal Chemistry. PMID 30095246 DOI: 10.1021/acs.jmedchem.7b01847 |
0.554 |
|
| 2018 |
Lian W, Jang J, Potisopon S, Li PC, Rahmeh A, Wang J, Kwiatkowski NP, Gray NS, Yang PL. Discovery of Immunologically Inspired Small Molecules that Target the Viral Envelope Protein. Acs Infectious Diseases. PMID 30027735 DOI: 10.1021/Acsinfecdis.8B00127 |
0.496 |
|
| 2018 |
de Wispelaere M, Lian W, Potisopon S, Li PC, Jang J, Ficarro SB, Clark MJ, Zhu X, Kaplan JB, Pitts JD, Wales TE, Wang J, Engen JR, Marto JA, Gray NS, et al. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chemical Biology. PMID 29937406 DOI: 10.1016/J.Chembiol.2018.05.011 |
0.495 |
|
| 2018 |
Giurisato E, Xu Q, Lonardi S, Telfer B, Russo I, Pearson A, Finegan KG, Wang W, Wang J, Gray NS, Vermi W, Xia Z, Tournier C. Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. Proceedings of the National Academy of Sciences of the United States of America. PMID 29507229 DOI: 10.1073/Pnas.1707929115 |
0.522 |
|
| 2018 |
Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid KE, Gustine J, Dubeau T, Severns P, Castillo JJ, ... ... Wang J, et al. BTKdrives ibrutinib resistance via ERK1/2, and protects BTKMYD88 mutated cells by a paracrine mechanism. Blood. PMID 29496671 DOI: 10.1182/Blood-2017-10-811752 |
0.483 |
|
| 2018 |
Tusa I, Gagliardi S, Tubita A, Pandolfi S, Urso C, Borgognoni L, Wang J, Deng X, Gray NS, Stecca B, Rovida E. ERK5 is activated by oncogenic BRAF and promotes melanoma growth. Oncogene. PMID 29483645 DOI: 10.1038/S41388-018-0164-9 |
0.583 |
|
| 2018 |
Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, et al. Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 Elife. DOI: 10.7554/Elife.39030.023 |
0.328 |
|
| 2018 |
Ott CJ, Szalat R, Lawlor M, Samur MK, Xu Y, Epstein CB, Lin CY, Prabhala R, Farrell N, Walter LD, Schwartz L, Wen K, Tai Y, Fulciniti M, Wang J, et al. Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma Blood. 132: 1313-1313. DOI: 10.1182/Blood-2018-99-119941 |
0.495 |
|
| 2018 |
Yang G, Wang J, Tan L, Liu X, Munshi M, Chen JG, Xu L, Tsakmaklis N, Demos M, Kofides A, Guerrera ML, Chan GG, Hunter ZR, Patterson C, Castillo JJ, et al. A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88 Blood. 132: 40-40. DOI: 10.1182/Blood-2018-99-119171 |
0.412 |
|
| 2018 |
Munshi M, Chen J, Liu X, Xu L, Tsakmaklis N, Demos M, Kofides A, Guerrera ML, Chan GG, Patterson C, Meid K, Gustine J, Castillo JJ, Hunter ZR, Wang J, et al. MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling Blood. 132: 4116-4116. DOI: 10.1182/Blood-2018-99-117372 |
0.331 |
|
| 2017 |
Wang B, Deng Y, Chen Y, Yu K, Wang A, Liang Q, Wang W, Chen C, Wu H, Hu C, Miao W, Hur W, Wang W, Hu Z, Weisberg EL, ... Wang J, et al. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. European Journal of Medicinal Chemistry. 137: 545-557. PMID 28628824 DOI: 10.1016/J.Ejmech.2017.06.016 |
0.573 |
|
| 2017 |
Mujahid N, Liang Y, Murakami R, Choi HG, Dobry AS, Wang J, Suita Y, Weng QY, Allouche J, Kemeny LV, Hermann AL, Roider EM, Gray NS, Fisher DE. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Reports. 19: 2177-2184. PMID 28614705 DOI: 10.1016/J.Celrep.2017.05.042 |
0.451 |
|
| 2017 |
Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, et al. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 6. PMID 28561737 DOI: 10.7554/Elife.24523 |
0.57 |
|
| 2017 |
Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J, Yu K, Hu C, Wang W, Liu X, Deng Y, et al. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports. 7: 466. PMID 28352114 DOI: 10.1038/S41598-017-00482-4 |
0.438 |
|
| 2017 |
Liang Y, de Wispelaere M, Carocci M, Liu Q, Wang J, Yang PL, Gray NS. Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. Acs Medicinal Chemistry Letters. 8: 344-349. PMID 28337328 DOI: 10.1021/Acsmedchemlett.7B00008 |
0.565 |
|
| 2017 |
Wein MN, Liang Y, Goransson O, Sundberg TB, Wang J, Williams EA, O'Meara MJ, Govea N, Beqo B, Nishimori S, Nagano K, Brooks DJ, Martins JS, Corbin B, Anselmo A, et al. Corrigendum: SIKs control osteocyte responses to parathyroid hormone. Nature Communications. 8: 14745. PMID 28224982 DOI: 10.1038/Ncomms14745 |
0.379 |
|
| 2017 |
Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang H, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, et al. Author response: Synergistic interactions with PI3K inhibition that induce apoptosis Elife. DOI: 10.7554/Elife.24523.023 |
0.442 |
|
| 2017 |
Yang G, Hatcher J, Wang J, Liu X, Munshi M, Chen J, Xu L, Tsakmaklis N, Demos M, Kofides A, Chan G, Hunter Z, Patterson C, Gustine J, Castillo JJ, et al. A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells Blood. 130: 719-719. DOI: 10.1182/Blood.V130.Suppl_1.719.719 |
0.49 |
|
| 2016 |
de Wispelaere M, Carocci M, Liang Y, Liu Q, Sun E, Vetter ML, Wang J, Gray NS, Yang PL. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Research. PMID 28034743 DOI: 10.1016/J.Antiviral.2016.12.017 |
0.513 |
|
| 2016 |
Beelontally R, Wilkie GS, Lau B, Goodmaker CJ, Ho CM, Swanson CM, Deng X, Wang J, Gray NS, Davison AJ, Strang BL. Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins. Antiviral Research. PMID 27956134 DOI: 10.1016/J.Antiviral.2016.12.006 |
0.544 |
|
| 2016 |
Zhang J, Gao G, Begum G, Wang J, Khanna AR, Shmukler BE, Daubner GM, de Los Heros P, Davies P, Varghese J, Bhuiyan MI, Duan J, Zhang J, Duran D, Alper SL, et al. Functional kinomics establishes a critical node of volume-sensitive cation-Cl(-) cotransporter regulation in the mammalian brain. Scientific Reports. 6: 35986. PMID 27782176 DOI: 10.1038/Srep35986 |
0.579 |
|
| 2016 |
Wein MN, Liang Y, Goransson O, Sundberg TB, Wang J, Williams EA, O'Meara MJ, Govea N, Beqo B, Nishimori S, Nagano K, Brooks DJ, Martins JS, Corbin B, Anselmo A, et al. SIKs control osteocyte responses to parathyroid hormone. Nature Communications. 7: 13176. PMID 27759007 DOI: 10.1038/Ncomms13176 |
0.509 |
|
| 2016 |
Wang A, Yan XE, Wu H, Wang W, Hu C, Chen C, Zhao Z, Zhao P, Li X, Wang L, Wang B, Ye Z, Wang J, Wang C, Zhang W, et al. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget. PMID 27626175 DOI: 10.18632/Oncotarget.11951 |
0.537 |
|
| 2016 |
Williams CA, Fernandez-Alonso R, Wang J, Toth R, Gray NS, Findlay GM. Erk5 Is a Key Regulator of Naive-Primed Transition and Embryonic Stem Cell Identity. Cell Reports. PMID 27498864 DOI: 10.1016/J.Celrep.2016.07.033 |
0.521 |
|
| 2016 |
Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, ... ... Wang J, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. PMID 27397505 DOI: 10.1016/J.Cell.2016.06.017 |
0.463 |
|
| 2016 |
Lee S, Shang Y, Redmond SA, Urisman A, Tang AA, Li KH, Burlingame AL, Pak RA, Jovičić A, Gitler AD, Wang J, Gray NS, Seeley WW, Siddique T, Bigio EH, et al. Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron. PMID 27321923 DOI: 10.1016/J.Neuron.2016.05.021 |
0.482 |
|
| 2016 |
Clark MJ, Miduturu C, Schmidt AG, Zhu X, Pitts JD, Wang J, Potisopon S, Zhang J, Wojciechowski A, Hann Chu JJ, Gray NS, Yang PL. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chemical Biology. 23: 443-452. PMID 27105280 DOI: 10.1016/J.Chembiol.2016.03.010 |
0.534 |
|
| 2016 |
Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen YF, Wang L, Gray NS, et al. Discovery of a Highly Selective STK16 Kinase Inhibitor. Acs Chemical Biology. PMID 27082499 DOI: 10.1021/Acschembio.6B00250 |
0.595 |
|
| 2015 |
Neel VA, Todorova K, Wang J, Kwon E, Kang M, Liu Q, Gray N, Lee SW, Mandinova A. Sustained Akt activity is required to maintain cell viability in seborrheic keratosis, a benign epithelial tumor. The Journal of Investigative Dermatology. PMID 26739095 DOI: 10.1016/J.Jid.2015.12.023 |
0.509 |
|
| 2015 |
Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. PMID 26677978 DOI: 10.1158/0008-5472.Can-15-0817 |
0.541 |
|
| 2015 |
Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, ... ... Wang J, et al. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget. PMID 26375053 DOI: 10.18632/Oncotarget.5182 |
0.54 |
|
| 2015 |
Wilhelmsen K, Xu F, Farrar K, Tran A, Khakpour S, Sundar S, Prakash A, Wang J, Gray NS, Hellman J. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Science Signaling. 8: ra86. PMID 26307013 DOI: 10.1126/Scisignal.Aaa3206 |
0.521 |
|
| 2015 |
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. PMID 26165234 DOI: 10.1038/Leu.2015.180 |
0.588 |
|
| 2015 |
Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. Plos One. 10: e0128364. PMID 26046350 DOI: 10.1371/Journal.Pone.0128364 |
0.58 |
|
| 2015 |
Wang J, Gray NS. SnapShot: Kinase Inhibitors II. Molecular Cell. 58: 710.e1. PMID 26000855 DOI: 10.1016/j.molcel.2015.05.002 |
0.518 |
|
| 2015 |
Wang J, Gray NS. SnapShot: Kinase Inhibitors I. Molecular Cell. 58: 708.e1. PMID 26000854 DOI: 10.1016/J.Molcel.2015.05.001 |
0.576 |
|
| 2015 |
Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 34: 2167-77. PMID 24909170 DOI: 10.1038/Onc.2014.161 |
0.456 |
|
| 2014 |
Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 111: E4869-77. PMID 25349422 DOI: 10.1073/Pnas.1403438111 |
0.52 |
|
| 2014 |
Derbyshire ER, Zuzarte-Luís V, Magalhães AD, Kato N, Sanschagrin PC, Wang J, Zhou W, Miduturu CV, Mazitschek R, Sliz P, Mota MM, Gray NS, Clardy J. Chemical interrogation of the malaria kinome. Chembiochem : a European Journal of Chemical Biology. 15: 1920-30. PMID 25111632 DOI: 10.1002/Cbic.201400025 |
0.546 |
|
| 2014 |
Vetter ML, Zhang Z, Liu S, Wang J, Cho H, Zhang J, Zhang W, Gray NS, Yang PL. Fluorescent visualization of Src by using dasatinib-BODIPY. Chembiochem : a European Journal of Chemical Biology. 15: 1317-24. PMID 24828915 DOI: 10.1002/Cbic.201402010 |
0.522 |
|
| 2014 |
Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. Acs Chemical Biology. 9: 1086-91. PMID 24556163 DOI: 10.1021/Cb4008524 |
0.576 |
|
| 2014 |
Ficarro SB, Biagi JM, Wang J, Scotcher J, Koleva RI, Card JD, Adelmant G, He H, Askenazi M, Marshall AG, Young NL, Gray NS, Marto JA. Protected amine labels: a versatile molecular scaffold for multiplexed nominal mass and sub-Da isotopologue quantitative proteomic reagents. Journal of the American Society For Mass Spectrometry. 25: 636-50. PMID 24496597 DOI: 10.1007/S13361-013-0811-X |
0.39 |
|
| 2014 |
Banerjee S, Buhrlage SJ, Huang HT, Deng X, Zhou W, Wang J, Traynor R, Prescott AR, Alessi DR, Gray NS. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. The Biochemical Journal. 457: 215-25. PMID 24171924 DOI: 10.1042/Bj20131152 |
0.599 |
|
| 2014 |
Maxson JE, Melissa AL, Wang J, Deng X, Luty SB, Sun H, Gorenstein J, Middleton R, Gray NS, Druker BJ, Tyner JW. Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations Blood. 124: 435-435. DOI: 10.1182/Blood.V124.21.435.435 |
0.541 |
|
| 2014 |
Kawano Y, Sahin I, Moschetta M, Wang J, Manier S, Glavey S, Mishima Y, Kokubun K, Tsukamoto S, Sacco A, Anderson KC, Roccaro AM, Gray NS, Ghobrial IM. Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells Blood. 124: 3430-3430. DOI: 10.1182/Blood.V124.21.3430.3430 |
0.492 |
|
| 2014 |
Kim H, Tan L, Weisberg EL, Liu F, Canning P, Choi H, Ezell S, Zhao Z, Wu H, Wang J, Mandinova A, Bullock AN, Liu Q, Lee SW, Gray NS. Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor Acs Chemical Biology. 9: 840-840. DOI: 10.1021/Cb5000949 |
0.504 |
|
| 2013 |
Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, Choi HG, Wang J, Dzamko N, Lee JD, Sim T, Kim N, Alessi DR, Lizcano JM, Knapp S, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. European Journal of Medicinal Chemistry. 70: 758-67. PMID 24239623 DOI: 10.1016/J.Ejmech.2013.10.052 |
0.679 |
|
| 2013 |
Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. Journal of the National Cancer Institute. 105: 1322-31. PMID 23940287 DOI: 10.1093/Jnci/Djt168 |
0.524 |
|
| 2013 |
Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. Acs Chemical Biology. 8: 2145-50. PMID 23899692 DOI: 10.1021/Cb400430T |
0.597 |
|
| 2013 |
Elkins JM, Wang J, Deng X, Pattison MJ, Arthur JS, Erazo T, Gomez N, Lizcano JM, Gray NS, Knapp S. X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. Journal of Medicinal Chemistry. 56: 4413-21. PMID 23656407 DOI: 10.1021/Jm4000837 |
0.507 |
|
| 2013 |
Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, et al. Discovery of a selective irreversible BMX inhibitor for prostate cancer. Acs Chemical Biology. 8: 1423-8. PMID 23594111 DOI: 10.1021/Cb4000629 |
0.553 |
|
| 2013 |
Jain R, Jain D, Liu Q, Bartosinska B, Wang J, Schumann D, Kauschke SG, Eickelmann P, Piemonti L, Gray NS, Lammert E. Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia. 56: 1350-5. PMID 23475368 DOI: 10.1007/S00125-013-2877-1 |
0.362 |
|
| 2013 |
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702 |
0.599 |
|
| 2012 |
Koliwad SK, Gray NE, Wang JC. Angiopoietin-like 4 (Angptl4): A glucocorticoid-dependent gatekeeper of fatty acid flux during fasting. Adipocyte. 1: 182-187. PMID 23700531 DOI: 10.4161/adip.20787 |
0.37 |
|
| 2012 |
Deng X, Zhou W, Weisberg E, Wang J, Zhang J, Sasaki T, Nelson E, Griffin JD, Jänne PA, Gray NS. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. Bioorganic & Medicinal Chemistry Letters. 22: 4579-84. PMID 22727638 DOI: 10.1016/J.Bmcl.2012.05.107 |
0.553 |
|
| 2012 |
Wang JC, Gray NE, Kuo T, Harris CA. Regulation of triglyceride metabolism by glucocorticoid receptor. Cell & Bioscience. 2: 19. PMID 22640645 DOI: 10.1186/2045-3701-2-19 |
0.351 |
|
| 2012 |
Gray NE, Lam LN, Yang K, Zhou AY, Koliwad S, Wang JC. Angiopoietin-like 4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes. The Journal of Biological Chemistry. 287: 8444-56. PMID 22267746 DOI: 10.1074/Jbc.M111.294124 |
0.393 |
|
| 2012 |
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. The Journal of Biological Chemistry. 287: 9742-52. PMID 22223645 DOI: 10.1074/Jbc.M111.304485 |
0.601 |
|
| 2012 |
Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, Gray NS. Development of ATP-competitive mTOR inhibitors. Methods in Molecular Biology (Clifton, N.J.). 821: 447-60. PMID 22125084 DOI: 10.1007/978-1-61779-430-8_29 |
0.553 |
|
| 2012 |
Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, Gray N. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. Acs Chemical Biology. 7: 185-96. PMID 21992004 DOI: 10.1021/Cb200305U |
0.603 |
|
| 2011 |
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Choi HG, Waller DL, Sim T, Sabatini DM, Gray NS. Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. Bioorganic & Medicinal Chemistry Letters. 21: 4036-40. PMID 21621413 DOI: 10.1016/J.Bmcl.2011.04.129 |
0.518 |
|
| 2011 |
Deng X, Wang J, Zhang J, Sim T, Kim ND, Sasaki T, Luther W, George RE, Jänne PA, Gray NS. Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. Acs Medicinal Chemistry Letters. 2: 379-384. PMID 21572589 DOI: 10.1021/Ml200002A |
0.515 |
|
| 2011 |
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. Journal of Medicinal Chemistry. 54: 1473-80. PMID 21322566 DOI: 10.1021/Jm101520V |
0.56 |
|
| 2010 |
Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. Journal of Medicinal Chemistry. 53: 7146-55. PMID 20860370 DOI: 10.1021/Jm101144F |
0.602 |
|
| 2009 |
Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today. Therapeutic Strategies. 6: 47-55. PMID 20622997 DOI: 10.1016/J.Ddstr.2009.12.001 |
0.556 |
|
| 2006 |
Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Human Genetics. 120: 589-601. PMID 16951947 DOI: 10.1007/S00439-006-0245-7 |
0.477 |
|
| 2005 |
Wang J, Li J, Chen HN, Chang H, Tanifum CT, Liu HH, Czyryca PG, Chang CWT. Glycodiversification for the optimization of the kanamycin class aminoglycosides Journal of Medicinal Chemistry. 48: 6271-6285. PMID 16190754 DOI: 10.1021/Jm050368C |
0.73 |
|
| 2005 |
Li J, Chen H, Chang H, Wang J, Chang CT. Tuning the Regioselectivity of the Staudinger Reaction for the Facile Synthesis of Kanamycin and Neomycin Class Antibiotics with N-1 Modification Organic Letters. 7: 3061-3064. PMID 15987205 DOI: 10.1021/Ol051045D |
0.451 |
|
| 2004 |
Wang J, Elchert B, Hui Y, Takemoto JY, Bensaci M, Wennergren J, Chang H, Rai R, Chang CW. Synthesis of trehalose-based compounds and their inhibitory activities against Mycobacterium smegmatis. Bioorganic & Medicinal Chemistry. 12: 6397-413. PMID 15556758 DOI: 10.1016/J.Bmc.2004.09.033 |
0.516 |
|
| 2004 |
Wang J, Li J, Czyryca PG, Chang H, Kao J, Chang CT. Synthesis of an unusual branched-chain sugar, 5-C-methyl-L-idopyranose for SAR studies of pyranmycins: implication for the future design of aminoglycoside antibiotics. Bioorganic & Medicinal Chemistry Letters. 14: 4389-4393. PMID 15357959 DOI: 10.1016/J.Bmcl.2004.06.064 |
0.443 |
|
| 2004 |
Elchert B, Li J, Wang J, Hui Y, Rai R, Ptak R, Ward P, Takemoto JY, Bensaci M, Chang CW. Application of the synthetic aminosugars for glycodiversification: synthesis and antimicrobial studies of pyranmycin. The Journal of Organic Chemistry. 69: 1513-23. PMID 14987005 DOI: 10.1021/Jo035290R |
0.503 |
|
| 2003 |
Li J, Wang J, Hui Y, Chang CT. Exploring the optimal site for modifications of pyranmycins with the extended arm approach. Organic Letters. 5: 431-434. PMID 12583736 DOI: 10.1021/Ol027288C |
0.41 |
|
| 2002 |
Chang CW, Hui Y, Elchert B, Wang J, Li J, Rai R. Pyranmycins, a novel class of aminoglycosides with improved acid stability: the SAR of D-pyranoses on ring III of pyranmycin. Organic Letters. 4: 4603-6. PMID 12489940 DOI: 10.1021/Ol0269042 |
0.5 |
|
| Show low-probability matches. |